Health Care • Biotechnology: Pharmaceutical Preparations
$11.04 ▼ -0.32
(-2.82%)
MKT CAP: $225.2M • VOL: 120.2K
52W L $10 52W H $23
KROS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $244.1M | $3.5M | $151.0K |
| YoY Revenue Growth % | +6775.0% | +2251.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $67.6M | -$210.8M | -$169.9M |
| Operating Margin % | 27.7% | -80.0% | -80.0% |
| Net Income (GAAP) | $87.0M | -$187.4M | -$153.0M |
| EBITDA (Normalized) | $68.8M | -$209.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $107.5M | -$160.9M | -$124.5M |
| Capital Expenditures (CapEx) | $1.6M | $1.9M | — |
| Free Cash Flow (FCF) | $106.0M | -$162.8M | -$124.5M |
| FCF Margin % | 43.4% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | 95.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $287.4M | $559.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $303.1M | $571.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KROS.